



SpectraCure: from university start-up to public company

Johannes Swartling, CTO

Lund, 5 April 2019


SpectraCure introduction




- Founded 2003 as a start-up from Lund University, Division of Atomic Physics
- Medical device company – interstitial photodynamic therapy (PDT)
- Focus on treatment of prostate cancer
- Currently: phase I-II clinical trials at Princess Margret Hospital in Toronto, Canada, Pennsylvania University Hospital in Philadelphia, USA, and University College London Hospital

Fotodynamic therapy - PDT

Triple component treatment



Interstitial PDT concept





SpectraCure P18

- 18 optical treatment fibres (18 lasers up to 600 mW each)
- Optical switch, treatment/monitoring
- IDOSE[®] treatment planning and dosimetry software
- CE-marked class IIb medical device for use with temoporfin (652 nm)
- Not yet CE-marked for use with verteporfin (690 nm)




Treatment overview



SpectraCure pre-history

- 1907: Discovery of PDT (von Tappeiner)
- 1988: First publication on PDT at Lund University
- 1998: Large grant by the Swedish Strategic Research Foundation (SSF)
- 2003: SpectraCure AB founded – Sune Svanberg, Katarina Svanberg, Stefan Andersson-Engels. Initial funding by Karolinska Development AB



SpectraCure history

- 2003-2009: Funded by Karolinska Development, Industrifonden, Östersjöstiftelsen (+ minor investors)
 - Development of SpectraCure P18 and IDOSE (652 nm)
 - Pilot clinical trial i Malmö and Stockholm
 - Focus on non-treated (primary) prostate cancer
- 2010: Company sold to Masoud Khayyami and group of private investors
 - Development of SpectraCure P18 and IDOSE (690 nm)
 - Focus on recurrent prostate cancer
 - Planning for clinical trial in Toronto and Philadelphia
- 2015: Initial public offering (IPO) at Aktietorget
- 2017: First patient treatment in Toronto
- 2018: Listed at Nasdaq First North

Current trial

- **Localised recurrent prostate cancer** (failed radiotherapy) as the route to market approval of the technology and clinical introduction
- Dose escalation trial (photosensitiser dose and light dose)
- Trial divided between Toronto, Philadelphia and London


Clinical situation



Treatment planning




Inserting needles




Treatment


Dose map examples



MR images



Pre-treatment



Post-treatment (7 days)



Thank you!

jsw@spectracure.com